Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis
| Autor: | Yoshiaki Nagai, Shinichiro Koyama, Nobuyuki Koyama, Fumiaki Kudo, Toshio Demitsu, Hiromitsu Ota, Hiroki Yabe, Chihiro Miwa, Yasutaka Watanabe, Koichi Hagiwara, Yuki Iwai |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Lung Neoplasms Erythema dermatomyositis Adenocarcinoma of Lung Antineoplastic Agents Case Report Adenocarcinoma Diagnosis Differential 03 medical and health sciences 0302 clinical medicine Internal Medicine medicine immune-related adverse event Humans Lung cancer 030203 arthritis & rheumatology nivolumab Muscle Weakness business.industry Muscle weakness Antibodies Monoclonal Heliotrope rash General Medicine Dermatomyositis medicine.disease Dermatology Magnetic Resonance Imaging lung cancer 030220 oncology & carcinogenesis Differential diagnosis medicine.symptom Nivolumab business |
| Zdroj: | Internal Medicine |
| ISSN: | 1349-7235 |
| Popis: | We herein report a 42-year-old man with advanced lung adenocarcinoma and nivolumab-associated dermatomyositis. Nivolumab, an anticancer drug that is classified as an immune checkpoint inhibitor, often induces immune-related adverse events (irAEs). However, there have so far been no reports regarding nivolumab-associated dermatomyositis. This patient was diagnosed with dermatomyositis due to the presence of proximal muscle weakness with abnormal electromyography and magnetic resonance imaging findings; skin lesions, such as heliotrope rash, shawl sign, and periungual erythema; and an elevated serum aldolase level after nivolumab administration. It is important to consider drug-associated dermatomyositis in the differential diagnosis of patients presenting with skin lesions and muscle weakness after nivolumab treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|